HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. (11th May 2020)

• Record Type: Journal Article
• Authors: Vivaldi, Caterina; Fornaro, Lorenzo; Ugolini, Clara; Niccoli, Cristina; Musettini, Gianna; Pecora, Irene; Cacciato Insilla, Andrea; Salani, Francesca; Pasquini, Giulia; Catanese, Silvia; Lencioni, Monica; Masi, Gianluca; Campani, Daniela; Fontantini, Gabriella; Falcone, Alfredo; Vasile, Enrico
• Is Part Of: Oncologist. Volume 25:Number 10(2020)
• Page Start: 886
• Page End: 893
• Publication Date: 2020-05-11
• Subjects: Biliary tract cancer -- HER2 -- Prognosis -- Cholangiocarcinoma -- Gallbladder cancer; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2019-0922
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: HER2 overexpression has been investigated as a potential biomarker and therapeutic target in biliary tract cancer (BTC), but a prognostic role of such alteration has not been demonstrated yet. Materials and Methods: We retrospectively evaluated HER2 protein expression by immunohistochemistry (IHC) in 100 patients with radically resected BTC. HER2 gene amplification was assessed by fluorescence in situ hybridization (FISH) in 2+ and 3+ cases at IHC. High HER2 protein expression was defined as either IHC 3+ or 2+ associated with FISH positivity. The primary objective of the study was to evaluate the prognostic role of HER2 overexpression in terms of disease‐free survival (DFS) and overall survival (OS). Secondary endpoints were the prevalence of HER2 overexpression and the possible correlation with other clinicopathological features. Results: HER2 overexpression was identified in 11 patients and was not related to other clinicopathological factors. DFS was significantly shorter in HER2‐positive compared with HER2‐negative patients (10.6 vs. 20.9 months, log‐rank p = .017). HER2 confirmed its prognostic value for DFS at multivariate analysis (hazard ratio 2.512; 95% confidence interval, 1.232–5.125; p = .011) together with nodal stage ( p < .001), resection margin ( p = .027), and tumor site ( p = .030). There was no difference in OS between HER2‐positive and ‐negative patients ( p = .068). Conclusion: HER2 overexpression represents an independent prognostic factor for disease recurrence in patients with BTC treated with potentially curative surgery. Abstract : Studies suggest that the HER2 pathway could play a role in the development and growth of biliary tract cancer. This study investigated the incidence and effect of HER2 expression on the risk of recurrence in a large series of resected biliary tract cancer cases at a single Institution.